Oculis (NASDAQ:OCS) Posts Quarterly Earnings Results, Misses Expectations By $0.28 EPS

Oculis (NASDAQ:OCS) issued its quarterly earnings results on Tuesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Oculis Stock Performance

NASDAQ OCS opened at $18.84 on Thursday. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average of $20.86 and a 200-day moving average of $16.88. Oculis has a 1-year low of $10.55 and a 1-year high of $23.08. The firm has a market cap of $763.10 million, a price-to-earnings ratio of -9.76 and a beta of 0.02.

Wall Street Analyst Weigh In

OCS has been the topic of a number of research reports. Robert W. Baird boosted their price objective on Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Thursday. Chardan Capital reissued a “buy” rating and issued a $28.00 price target on shares of Oculis in a research report on Thursday. Finally, HC Wainwright decreased their price objective on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a report on Thursday.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.